Archives

img-01

Japan Pharmaceutical Updates

On March 18, the Japanese MHLW announced six goals to strengthen their clinical trial capabilities. First, Japan wants to build a more advanced, first-class clinical trial regime to enhance and promote local clinical trials. Second, the MHLW hopes to build a better infrastructure... Read More

img-01

Japan’s MHLW Now Accepts Annual Reports for CMC Changes

Japan’s Ministry of Health, Labour and Welfare (MHLW) is loosening a policy regarding post-approval changes in manufacturing, allowing pharmaceutical companies to submit “annual reports” rather than “minor change notifications” for minor changes with minimal effects on product quality. The relaxation of this rule... Read More

img-01

Quick Asian Regulatory Updates

Japan’s Ministry of Health, Labor, and Welfare (MHLW) granted orphan drug designations to 15 drug compounds on February 28, including Novartis Pharma’s atrasentan for IgA nephropathy. Other drugs given this designation include Alexion’s efzimfotase alfa (hypophosphatasia), HanAll Biopharma’s batoclimab (thyroid eye disease),... Read More

img-01

Japan Updates 2025 NHI Drug Prices

On December 20, 2024, the Japanese Fiscal Year 2025 NHI drug price revision was implemented. Price revisions in Japan are based on the “discrepancy rates” between the current NHI prices and the actual market prices obtained in the 2024 drug price survey. For... Read More